Amerge Related Published Studies
Well-designed clinical trials related to Amerge (Naratriptan)
Published and not fully published double-blind, randomised, controlled trials
with oral naratriptan in the treatment of migraine: a review based on the GSK
Trial Register. [2011]
Efficacy of oral naratriptan in the treatment of menstrually related migraine. [2005.10]
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. [2003.11]
Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. [2003.09]
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. [2001.03]
Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. [2000.08]
Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. [2000.08]
Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. [2000.07.12]
Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. [2000.07]
Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. [1999]
Effect of subcutaneous naratriptan on forearm blood flow. [1998.09]
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group. [1997.12]
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group. [1997.11]
Well-designed clinical trials possibly related to Amerge (Naratriptan)
Reduced efficacy of sumatriptan in migraine with aura vs without aura. [2015]
Sumatriptan plus naproxen for acute migraine attacks in adults. [2013]
Triptans in prevention of menstrual migraine: a systematic review with
meta-analysis. [2013]
Frovatriptan for prophylactic treatment of cluster headache: lessons for future trial design. [2011.01]
Frovatriptan for prophylactic treatment of cluster headache: lessons for future
trial design. [2011]
Acute treatment and prevention of menstrually related migraine headache: evidence-based review. [2008.04.22]
Out-patient detoxification in chronic migraine: comparison of strategies. [2003.12]
Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. [2003.12]
Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. [2002]
The scientific basis of medication choice in symptomatic migraine treatment. [1999.11]
Other research related to Amerge (Naratriptan)
Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. [2011.08]
Pure naratriptan-induced ischemic colitis: a case report. [2010.03]
The safety of sumatriptan and naratriptan in pregnancy: what have we learned? [2009.11]
Halide salts of antimigraine agents eletriptan and naratriptan. [2008.12]
Temporary confusion depending on the usage of naratriptan. [2007.12]
[The Vigimig study of naratriptan use in general practice] [2007.11]
Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. [2007.10]
[The Vigimig study of naratriptan use in general practice.] [2007.07.28]
Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. [2007.07]
Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine. [2007.06]
Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study. [2005.11]
Preclinical neuropharmacology of naratriptan. [2005.09]
Naratriptan in the short-term prophylaxis of pure menstrual migraine. [2005.05]
Ischemic colitis associated with naratriptan and oral contraceptive use. [2005.04]
Colonic ischemia associated with naratriptan use. [2004.10]
Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. [2004.08.10]
The sumatriptan/naratriptan aggregated patient (SNAP) database: aggregation, validation and application. [2004.07]
Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. [2004.02]
Managing intractable migraine with naratriptan. [2003.10]
Investigation of the effects of naratriptan, rizatriptan, and sumatriptan on jugular venous oxygen saturation in anesthetized pigs: implications for their mechanism of acute antimigraine action. [2003.10]
Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases. [2003.05]
Naratriptan in the preventive treatment of cluster headache. [2002.12]
Naratriptan in the prophylaxis of cluster headache. [2002.01]
Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. [2001.08]
Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. [2001.07]
Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. [2001.05]
Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. [2001.02]
Naratriptan. [2001]
[Quality of life of migraine patients after treatment with 2.5 mg oral naratriptan] [2000.12.09]
Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. [2000.08]
Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group. [2000.06]
Prevention of migraine during prodrome with naratriptan. [2000.03]
Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. [2000.02]
Naratriptan. [1999.10]
Naratriptan in the prophylaxis of transformed migraine. [1999.07]
Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. [1999.07]
Naratriptan: an alternative for migraine. [1999.06]
[Pharmacy-clinic medication of the month. Naratriptan (naramig)] [1999.03]
Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. [1998.09]
Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group. [1998.01]
Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. [1997.11]
A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. [1997.04]
Other possibly related research studies
Eletriptan review. [2005.04]
Correlation between lipophilicity and triptan outcomes. [2005.01]
Cost considerations of acute migraine treatment. [2004.03]
Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. [2003.07]
Comparative aspects of triptans in treating migraine. [2001]
Validation of the Patient Perception of Migraine Questionnaire. [2002.09]
Triptans reduce the inflammatory response in bacterial meningitis. [2002.08]
Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. [2002.02]
Acute treatment of migraine and the role of triptans. [2001.03]
Clinical features of withdrawal headache following overuse of triptans and other headache drugs. [2001.11.13]
Comparison of rizatriptan and other triptans on stringent measures of efficacy. [2001.10.23]
Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. [2001.09]
Establishing a standard of speed for assessing the efficacy of the serotonin(1B/1D) agonists (triptans). [2001.07]
Gastric motor effects of triptans: open questions and future perspectives. [2001.03]
Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? [2000.10]
Treatment of acute migraine attacks. [2000.09]
Current and emerging second-generation triptans in acute migraine therapy: a comparative review. [2000.07]
Newer intranasal migraine medications. [2000.01.01]
Acute management of migraine: triptans and beyond. [1999.06]
Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. [1999.06]
[Zolmitriptan] [1998.12]
Coronary side-effect potential of current and prospective antimigraine drugs. [1998.07.07]
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. [1997.06]
The use of triptans in the management of menstrual migraine. [2005]
[The role of triptans and analgesics for primary headache treatment] [2005.10]
An economic evaluation of rizatriptan in the treatment of migraine. [2005]
Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. [2005.05]
[Economic evaluation of acute migraine attack treatment with triptans in Spain] [2005.04]
The use of multiattribute decision models in evaluating triptan treatment options in migraine. [2005.09]
Triptan nonresponder studies: implications for clinical practice. [2005.02]
Migraine: pathophysiology, pharmacology, treatment and future trends. [2003.03]
Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. [2004.07]
Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes. [2004.06]
Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. [2004.06]
Triptans and gastric accommodation: pharmacological and therapeutic aspects. [2004.01]
Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. [2003.01]
|
